Pulse Biosciences (NASDAQ:PLSE) COO Liane Rae Teplitsky Buys 1,024 Shares

Posted by Francis Steltz on Sep 2nd, 2026

Pulse Biosciences, Inc (NASDAQ:PLSE – Get Free Report) COO Liane Rae Teplitsky acquired 1,024 shares of the business’s stock in a transaction dated Monday, August 31st. The stock was purchased at an average cost of $48.80 per share, with a total value of $49,971.20. Following the transaction, the chief operating officer owned 3,094 shares of the company’s stock, valued at approximately $150,987.20. The trade was a 49.47% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

Liane Rae Teplitsky also recently made the following trade(s):

On Tuesday, September 1st, Liane Rae Teplitsky bought 1,001 shares of Pulse Biosciences stock. The shares were purchased at an average price of $49.95 per share, for a total transaction of $49,999.95.
On Friday, August 28th, Liane Rae Teplitsky bought 1,034 shares of Pulse Biosciences stock. The stock was purchased at an average cost of $48.35 per share, with a total value of $49,993.90.
On Wednesday, August 26th, Liane Rae Teplitsky purchased 1,036 shares of Pulse Biosciences stock. The shares were acquired at an average cost of $48.23 per share, for a total transaction of $49,966.28.

Pulse Biosciences Stock Up 1.1%

Shares of PLSE stock traded up $0.59 during mid-day trading on Wednesday, hitting $52.68. 977,767 shares of the company’s stock were exchanged, compared to its average volume of 461,050. Pulse Biosciences, Inc has a fifty-two week low of $12.56 and a fifty-two week high of $54.39. The stock has a 50-day simple moving average of $36.93 and a two-hundred day simple moving average of $27.60. The stock has a market cap of $3.65 billion, a price-to-earnings ratio of -44.64 and a beta of 1.63.

Pulse Biosciences (NASDAQ:PLSE – Get Free Report) last released its earnings results on Thursday, August 6th. The company reported ($0.36) EPS for the quarter, missing the consensus estimate of ($0.29) by ($0.07). Pulse Biosciences had a negative net margin of 6,755.78% and a negative return on equity of 94.42%. The business had revenue of $0.43 million during the quarter, compared to analyst estimates of $0.53 million. As a group, analysts anticipate that Pulse Biosciences, Inc will post -1.29 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several brokerages have recently weighed in on PLSE. Wall Street Zen upgraded shares of Pulse Biosciences from a “sell” rating to a “hold” rating in a report on Saturday. Oppenheimer reaffirmed an “outperform” rating on shares of Pulse Biosciences in a research report on Tuesday, July 28th. Weiss Ratings restated a “sell (d-)” rating on shares of Pulse Biosciences in a research note on Friday, July 17th. Mizuho set a $45.00 price objective on Pulse Biosciences in a report on Monday, August 10th. Finally, Needham & Company LLC assumed coverage on shares of Pulse Biosciences in a research report on Monday, August 17th. They set a “buy” rating and a $58.00 target price for the company. Four investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $45.25.

View Our Latest Analysis on PLSE

Institutional Investors Weigh In On Pulse Biosciences

Hedge funds have recently modified their holdings of the stock. Osterweis Capital Management Inc. purchased a new position in Pulse Biosciences in the 2nd quarter worth approximately $28,000. BNP Paribas Financial Markets boosted its stake in shares of Pulse Biosciences by 63.6% in the second quarter. BNP Paribas Financial Markets now owns 1,749 shares of the company’s stock valued at $26,000 after purchasing an additional 680 shares during the period. Tower Research Capital LLC TRC boosted its stake in shares of Pulse Biosciences by 275.0% in the second quarter. Tower Research Capital LLC TRC now owns 2,940 shares of the company’s stock valued at $44,000 after purchasing an additional 2,156 shares during the period. Russell Investments Group Ltd. grew its holdings in Pulse Biosciences by 44.0% during the 3rd quarter. Russell Investments Group Ltd. now owns 4,487 shares of the company’s stock valued at $79,000 after purchasing an additional 1,372 shares in the last quarter. Finally, Jupiter Topco LLC purchased a new stake in Pulse Biosciences during the 2nd quarter worth $241,000. 76.95% of the stock is currently owned by hedge funds and other institutional investors.

Pulse Biosciences Company Profile

(Get Free Report)

Pulse Biosciences, Inc is a clinical-stage bioelectric medicine company that develops and commercializes medical devices based on its proprietary Tissue NanoPoration (TNP) platform. The company’s core technology, NanoPulse Stimulation (NPS), delivers ultrashort, high-voltage electric pulses to targeted tissue, triggering cellular responses without the thermal damage associated with traditional energy-based devices. Pulse Biosciences focuses on applications in dermatology and aesthetic medicine, where controlled ablation of unwanted lesions is critical.

The company’s flagship product, the CellFX® System, is designed to treat a range of benign and malignant skin lesions, including seborrheic keratosis, non-melanoma skin cancers, and various epidermal and dermal lesions.